Shanghai Sanyou Medical (SH:688085)2024-04-25 08:26Financial Performance - The company expects a net profit attributable to shareholders of 95.5829 million yuan for 2023, exceeding the previous forecast upper limit by 582,900 yuan[5]. - The net profit for 2023 represents a decrease of 49.91% compared to the previous year's net profit of 190.8183 million yuan[5][6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be 59.2846 million yuan, a decline of 55.70% from the previous year's figure of 133.8225 million yuan[5][6]. Forecast Discrepancies - The initial profit forecast was made without complete investment target assessment data, leading to discrepancies between estimated and actual figures[7]. - The company has communicated with its accounting firm regarding the profit forecast, and there are no significant discrepancies between the two parties[8]. - The board of directors has expressed sincere apologies for the impact of the profit forecast discrepancies on investors[11]. Future Improvements - The company aims to enhance management practices and improve the quality of financial information in future forecasts[11]. - The financial data provided is subject to final auditing, and investors are advised to be cautious regarding investment risks[10]. - The company will disclose the audited financial data in the 2023 annual report[9]. Performance Period - The performance forecast period is from January 1, 2023, to December 31, 2023[3].